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Objective: Estimates of incident dementia, and cognitive impairment, not dementia (CIND) (or the related mild
cognitive impairment) are important for public health and clinical care policy. In this paper, we report US national
incidence rates for dementia and CIND.
Methods: Participants in the Aging, Demographic, and Memory Study (ADAMS) were evaluated for cognitive
impairment using a comprehensive in-home assessment. A total of 456 individuals aged 72 years and older, who
were not demented at baseline, were followed longitudinally from August 2001 to December 2009. An expert
consensus panel assigned a diagnosis of normal cognition, CIND, or dementia and its subtypes. Using a population-
weighted sample, we estimated the incidence of dementia, Alzheimer disease (AD), vascular dementia (VaD), and
CIND by age. We also estimated the incidence of progression from CIND to dementia.
Results: The incidence of dementia was 33.3 (standard error [SE], 4.2) per 1,000 person-years and 22.9 (SE, 2.9) per
1,000 person-years for AD. The incidence of CIND was 60.4 (SE, 7.2) cases per 1,000 person-years. An estimated
120.3 (SE, 16.9) individuals per 1,000 person-years progressed from CIND to dementia. Over a 5.9-year period,
about 3.4 million individuals aged 72 and older in the United States developed incident dementia, of whom
approximately 2.3 million developed AD, and about 637,000 developed VaD. Over this same period, almost 4.8
million individuals developed incident CIND.
Interpretation: The incidence of CIND is greater than the incidence of dementia, and those with CIND are at high
risk of progressing to dementia, making CIND a potentially valuable target for treatments aimed at slowing cognitive
decline.
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The rapid growth in the number of older adults in theUnited States puts an increasing number of individu-
als at risk for cognitive impairment and dementia. As a
result of this demographic shift in the population, the prev-
alence of Alzheimer disease (AD) is estimated to grow to
nearly 9 million individuals in North America by 2050.1
Previous estimates of the incidence of dementia and AD in
the United States for individuals aged 65 years and older
primarily have been extrapolated from data on local or re-
gional samples. These estimates range from 20 to 43 cases
per 1,000 person-years for dementia2–6 and from 14 to 27
cases per 1,000 person-years for AD.2–3,5,7,8
Fewer estimates are available for the incidence of
milder impairment that does not reach the severity of
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dementia, often termed mild cognitive impairment
(MCI) or cognitive impairment, not dementia (CIND).
The criteria for CIND and MCI have grown more simi-
lar over time,9 with the 1 remaining difference being
that CIND requires either complaint of a problem or
impaired test performance,10 and MCI requires both
complaint of a problem and impaired test performance.11
This difference in criteria for CIND and MCI does not
appear to account for the broad variability in estimated
incidence rates for mild impairment,12 which range from
22 to 51 cases per 1,000 person-years.13–15 Although
incidence estimates for MCI and CIND vary, there is
general agreement that individuals with cognitive impair-
ment are at higher risk of progressing to dementia com-
pared to older individuals with normal cognition.
Estimates of the incidence of CIND and dementia
are essential to provide benchmarks against which to
assess trends in incidence rates over time and to assess
the effect of preventative measures devoid of survival
effects that can bias prevalence estimates. Both the large
numbers of individuals affected with CIND or dementia
and the conditions’ broad impact on the individual’s
health, family resources, and healthcare mean that even
small benefits from future interventions may have a sig-
nificant impact on disease burden in the United States.
The Aging, Demographics, and Memory Study
(ADAMS) uses a national probability sample that includes
individuals from all regions of the United States and pro-
vides a unique resource to estimate incidence rates for de-
mentia, AD, and CIND. As a longitudinal study, it is also
able to assess rates of progression from CIND to dementia
and better identify the full implications of cognitive
impairment for public health and clinical care policy.
Subjects and Methods
Sample
The ADAMS sample was drawn from the larger Health and
Retirement Study (HRS), an ongoing national probability cohort
study of individuals born prior to 1960, designed to investigate
the health, social, and economic implications of the aging of the
American population.16–18 The HRS began in 1992, and the cur-
rent sample includes approximately 22,000 individuals.
The ADAMS began with a stratified random subsample
of 1,770 individuals from the approximately 7,000 HRS
respondents aged 70 years old who completed the 2000 or
2002 wave of HRS. Participants in the full ADAMS sample
lived in 42 states distributed throughout all census regions of
the United States. To achieve a sufficient number of ADAMS
respondents across the full range of cognitive ability, the sample
was stratified based on cognitive screening scores on the HRS.
Respondents were each classified into 1 of 5 cognitive strata,
ranging from low to high cognition based on their HRS cogni-
tive screening scores. For respondents who completed the HRS
interview themselves, the score from an abbreviated version of
the modified Telephone Interview for Cognitive Status19 was
used to assign them to a stratum. For respondents unable to
complete the interview themselves, a proxy for the respondent
completed the Informant Questionnaire on Cognitive Decline
in the Elderly (IQCODE),20 which assessed changes in the
respondent’s cognitive and functional ability. These respondents
were classified based on the IQCODE scores. The highest 3
cognitive strata were further stratified by age (70–79 years vs
80 years) and sex, to ensure adequate numbers in each sub-
group. Additional details of the ADAMS sample design are
described elsewhere.21,22
The Figure summarizes the number of participants at
each phase of the study; additional details on participation rates
have been reported previously.22 The initial ADAMS assess-
ments (Wave A) were conducted from 2001 to 2003 and
occurred on average 13.3 (standard deviation [SD], 6.9)
months after the HRS interview. Three waves of follow-up
assessments have been conducted on this sample. For the first
follow-up wave (Wave B), a subset of ADAMS participants (see
Fig) was selected to undergo an assessment approximately 16 to
18 months after the initial assessment if: (1) they received an
initial diagnosis of cognitive impairment without dementia; or
(2) they received an initial diagnosis of normal or demented,
but the consensus diagnostic panel thought the initial assess-
ment findings were ambiguous and longitudinal follow-up
would help clarify the diagnosis. A second follow-up (Wave C)
was done beginning in 2006 among the living participants not
previously diagnosed with dementia in the ADAMS. The Wave
C assessment took place on average 3.69 (range, 1.25–6.00)
years after the participant’s prior ADAMS assessment. Finally,
beginning in 2008, the third follow-up (Wave D) was con-
ducted an average of 1.8 years (range, 1.25–6.50) after the
most recent assessment. The assessment protocols for the initial
and follow-up assessments were similar, with only minor modi-
fications in the assessment measures. The sample for the present
analyses includes 456 individuals, spanning 36 states, who par-
ticipated in the first wave (Wave A) of ADAMS data collection
and who were not diagnosed with dementia at that wave.
All ADAMS data are publicly available and can be
obtained from the HRS website.23 The institutional review
boards at Duke University Medical Center and the University
of Michigan approved all study procedures, and study partici-
pants or their surrogates provided informed consent.
Dementia Assessment and Diagnosis
All participants were assessed for cognitive impairment in-per-
son in their residence by a nurse and neuropsychology techni-
cian. The full details of these assessment and diagnostic proce-
dures have been previously described.22 Briefly, an informant
(usually a spouse or adult child) was identified by the respond-
ent as someone who was knowledgeable about the respondent’s
daily activities and health issues. The following information
about the respondent was collected from the informant: (1) a
detailed chronological history of cognitive and functional
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symptoms, (2) medical history, (3) current medications, (4) cur-
rent neuropsychiatric symptoms, (5) measures of severity of cogni-
tive and functional impairment, and (6) family history of mem-
ory problems. During the assessment, each respondent completed:
(1) a battery of neuropsychological measures, (2) a self-report
depression measure, (3) a standardized neurological examination,
(4) a blood pressure measure, (5) collection of buccal DNA sam-
ple for APOE genotyping, and (6) a 7-minute videotaped seg-
ment covering portions of the cognitive status and neurological
examinations. The neuropsychological battery has been described
elsewhere,22 and included measures of orientation, verbal and vis-
ual immediate and delayed memory, language, attention, executive
function, praxis, and reading ability. Medical record releases were
also sought to obtain relevant prior neuroimaging and laboratory
results from participants’ physicians.
Final diagnoses were assigned by a consensus expert panel
made up of neuropsychologists, a cognitive neuroscientist, neu-
rologists, geropsychiatrists, and internists. The consensus panel
reviewed all information collected during the in-home assess-
ment and assigned a diagnosis in 2 stages, first without the
medical records and then with the medical records. As part of
the consensus process, the panel compared performance on the
neuropsychological tests from all assessments, but the consensus
panel was blind to the cognitive diagnosis assigned at the previ-
ous assessments. All individuals involved in the clinical assess-
ments or diagnosis of ADAMS participants were blind to the
participants’ HRS cognitive screening scores.
Diagnoses fell within the 3 general categories: normal cog-
nitive function, CIND, and dementia. The dementia diagnosis
was anchored by the Diagnostic and Statistical Manual of Mental
Disorders (DSM)-III-R24 and DSM-IV25 criteria, but the final di-
agnosis was based on the clinical judgment of the consensus
panel. Currently accepted diagnostic criteria were used for AD26
and vascular dementia (VaD), as adapted for research studies.27
These assessment and diagnostic procedures for AD have been
validated against neuropathological diagnoses.28
The criteria for CIND are less well-established than the
criteria for dementia. In the ADAMS, the diagnosis of CIND
was determined by clinical judgment, but was anchored in the
following guidelines: cognitively not normal but not demented;
self and/or informant report of problems with cognition or
daily activities; or performance on neuropsychological measures
that was both below expectation relative to education, reading
level, and occupational attainment, and at least 1.5 SDs below
published norms on at least 1 test. These CIND criteria are
similar to those currently used for MCI,11 except that the latter
require both self and/or informant complaint and impairment
on neuropsychological measures.
To reflect that dementia and CIND are often the conse-
quence of >1 pathological process, when appropriate we assigned
a primary and secondary diagnosis denoting these multiple etiolo-
gies. Dementia onset was estimated as the age at which the indi-
vidual met criteria for dementia based on a systematic review of
the chronological history of cognitive and functional changes.
FIGURE: Flowchart of number of participants at each phase of the study. *Includes 16 incident cognitive impairment, not de-
mentia (CIND) cases excluded from incidence analysis because of nonresponse (part of the cases not assessed at Wave C and/
or Wave D ‘‘due to other reasons’’).
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Analyses
Population sample weights were constructed to take into
account the probabilities of selection in the stratified longitudi-
nal sample design and to adjust for differential participation in
ADAMS at each assessment wave. Details of the development
of these weights are described in a technical report elsewhere.21
We compared sample characteristics by final cognitive status
using the Wald chi-square test for categorical measures and the
t test for continuous measures. Using the ADAMS sample
weights, we estimated the national incidence of CIND and de-
mentia (as well as the dementia subtypes AD and VaD) as the
number of individuals affected per 1,000 person-years by 8- or
10-year age at follow-up categories.
To examine possible predictors of incident cognitive
impairment reported in other studies, we used logistic regres-
sion to estimate the likelihood of dementia, AD, and CIND
first as a function of age and then as a function of age and
each of the following variables individually: education, gender,
race, and APOE genotype. We then created models with all of
the variables included. The results for each of the variables in
the full models were similar to those for the reduced models, so
we report only the full models in the Results section. For the
estimation of incidence rates, person-years were calculated for
each case as the number of years from the baseline assessment
until the first of any of the following events: (1) the event of
interest (dementia onset, for example), (2) death, or (3) com-
pletion of the final follow-up assessment (Wave D).
All analyses were conducted in SAS version 9.2 (SAS
Institute, Cary, NC) using procedures that account for the
influence of the weighting and other complex sample design
features.
Results
The Figure shows the number of individuals in each out-
come category for each phase of the study. Table 1 pro-
vides sample characteristics of individuals based on cog-
nitive status at follow-up. Individuals who did not
participate at Wave C or Wave D (n ¼ 92) due to ill-
ness, refusal, or being unable to be located did not differ
from participants on baseline age, years of education,
APOE e4 allele status, or mean Mini-Mental State Exam-
ination score; but they did differ on ethnicity, in that
Hispanics made up 11.6% of nonparticipants but only
4.1% of participants. Participants were followed an aver-
age of 4.89 (SD, 1.76) years. The mean estimated age of
onset for incident dementia was 83.72 years (SD, 5.49),
and the estimated mean age at first diagnosis for those
with incident CIND was 82.83 years (SD, 5.35).
Table 2 shows rates of incident CIND, AD, and
dementia by age at follow-up. The incidence of dementia
increased progressively with age, reaching 82 cases per
1,000 person-years for individuals aged >90 years. AD
incidence also increased with age and accounted for
>70% of the dementia cases overall. The incidence of
VaD (n ¼ 16) overall was 6.2 (95% confidence interval
[CI], 1.7–10.7) cases per 1,000 person-years. VaD inci-
dence increased from 2.1 (95% CI, 0.0–4.9) cases per
1,000 person-years for those aged 72 to 79 years to 11.4
(95% CI, 1.9–20.9) for those aged 80 to 89 years; how-
ever, there were no additional cases of vascular dementia
for those aged 90 and older. Overall, we found that an
estimated 3.4 million individuals aged 72 and older in
the United States developed incident dementia over a fol-
low-up period of 5.9 years, of whom approximately 2.3
million developed AD and 636,825 developed VaD.
Table 2 also shows that the incidence of CIND
progressively increased with age, and at each age stratum
the incidence of CIND was higher than the incidence of
dementia. When limiting the analyses just to those with
CIND, the incidence rate at which individuals with
CIND progressed to dementia was 120.3 cases per 1,000
person-years. In contrast, the incidence rate of conversion
to dementia among those with normal cognition was
17.1 cases per 1,000 person-years, a rate 7 lower than
among the CIND group. Even so, it is important to
note that among the 214 individuals with CIND at base-
line who were followed longitudinally, 110 retained their
CIND designation throughout the period that they were
followed, which suggests that progression to dementia
may not be inevitable among individuals in this group.
Twenty-five individuals (11.7%) with CIND at baseline
reverted to normal cognition at a subsequent follow-up
assessment, but 15 of these 25 then later reverted back to
CIND, and 5 individuals progressed to dementia after
further longitudinal follow-up. Over an average follow-
up period of 4.8 years, an estimated 4.8 million individ-
uals aged 72 and older in the United States developed
incident CIND. Based on these national estimates, indi-
viduals who progress from CIND to dementia account
for 75% of all incident cases of dementia.
Table 3 shows the results of the full logistic models
predicting dementia, AD, and CIND. Older age and
fewer years of education tended to be associated with a
higher risk of AD and dementia among all participants;
the odds ratios for the 3 cognitive outcomes were similar,
but only some of the values reached standard significance
levels. The presence of at least 1 APOE e4 allele was
associated with increased risk of incident dementia, AD,
and CIND. There was no significant association between
race and the incidence of CIND, dementia or AD
among all participants, whereas being male was associated
with decreased risk of AD.
When limiting the group to those with CIND,
males had a lower risk of progressing to dementia than
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females (odds ratio [OR], 0.59; 95% CI, 0.36–0.97) (see
Table 3). The association between APOE e4 carriers and
progression to dementia was significant (OR, 2.76; 95%
CI, 1.27–5.97). Age, education, and race were not associ-
ated with progression from CIND to dementia.
Discussion
We estimate that about 3.4 million new cases of demen-
tia occur during 6 years of follow-up for a US cohort
that is aged 72þ years at baseline; approximately 2.3
million of these individuals have AD. Almost 4.8 million
individuals are estimated to develop incident CIND dur-
ing the same time period, which is approximately 40%
more than the number of incident dementia cases of AD
in this age group in the United States. These are the first
estimates of the incidence of AD, dementia, and CIND
in a national probability US sample. Direct comparisons
to other studies of dementia and AD incidence estimates
are difficult due to differences in the age structure of the
samples and the reporting of different age strata among
the various studies. However, estimates of the incidence
of dementia and AD from ADAMS are broadly within
the midrange of estimates reported by other studies in
the United States and Canada.2–7,29 We note that the
other studies used age 65 years as the lower limit;
ADAMS incidence rates would likely have been lower if
its age range were lowered from 72 to 65 years. Brook-
meyer and colleagues1 developed an equation for age-spe-
cific AD incidence rates based on a review of the world-
wide literature. Applying this equation to US 2004 life
tables,30 the estimated incidence of AD for ages 72 to 79
years would be 8.5 cases per 1,000 person-years, 25.6
cases per 1,000 person-years for ages 80 to 89 years, and




















Dementia 72–79 22 938,949 49,574,616 18.9 (4.3) 10.1–27.8
80–89 58 1,965,362 46,528,062 42.2 (7.9) 26.0–58.5
90þ 26 503,009 6,127,925 82.1 (20.5) 39.9–124.3
Total 106 3,407,320 102,230,604 33.3 (4.2) 24.7–42.0
AD 72–79 16 821,592 49,574,616 16.6 (4.2) 8.0–25.1
80–89 39 1,127,323 46,528,062 24.2 (4.5) 15.0–33.4
90þ 22 392,057 6,127,925 64.0 (15.7) 31.8–96.2
Total 77 2,340,972 102,230,604 22.9 (2.9) 17.0–28.8
CIND 72–79 38 1,653,503 42,034,445 39.3 (8.2) 22.5–56.2
80–89 45 2,538,220 34,701,193 73.1 (11.8) 48.8–97.5
90þ 10 630,925 3,057,444 206.4 (56.1) 91.1–321.6
Total 93 4,822,649 79,793,083 60.4 (7.2) 45.6–75.3
Dementia
(among CIND) 72–79 19 741,835 7,253,899 102.3 (21.8) 57.5–147.0
80–89 50 1,474,533 10,988,270 123.8 (26.5) 679.3–178.4
90þ 21 341,135 2,737,281 124.6 (35.6) 51.4–197.8
Total 90 2,557,503 21,259,407 120.3 (16.9) 85.6–155.0
Total sample size for incident dementia and AD analyses ¼ 456; total sample size for incident CIND analysis ¼ 266; total sample
size for incident dementia among CIND group ¼ 268; total sample size for incident dementia from normal group ¼ 242.
Number of incident CIND is 11 more than in Table 1 because Table 2 numbers for incident CIND include the 11 individuals
who developed incident CIND and then progressed to incident dementia.
AD ¼ Alzheimer disease; CIND ¼ cognitive impairment, not dementia; SE ¼ standard error; CI ¼ confidence interval.
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76.7 cases per 1,000 person-years for those aged 90 years
and older.1 Although these estimated incidence rates are
remarkably close to those found in ADAMS for individ-
uals aged 80 years and older, the AD incidence rates
from ADAMS for ages 72 to 79 years are higher than
those estimated by the Brookmeyer equation. Notably,
however, this is the age group in which the literature
review1 found the most heterogeneity among estimates
worldwide and in which the US estimates were generally
among the highest worldwide.
Few studies worldwide and even fewer US studies
have estimated the incidence of mild impairment, labeled
as either CIND or MCI. Differences in case ascertain-
ment and diagnostic criteria make it difficult to compare
studies, but our estimate of 60 cases per 1,000 person-
years is slightly higher than 1 other multiethnic US
study.14 Although most studies report an increased risk
of dementia among those with various forms of mild
cognitive impairment, the estimates of rates of progres-
sion have varied widely. One study compared rates of
progression for 16 different diagnostic definitions of
mild impairment and found that the rates of progression
to dementia over 2 years ranged from 0.3% to 29%.31
Generally the definitions that allowed for impairment in
both memory and nonmemory domains, similar to that
used in the present study, resulted in the highest rates of
conversion to dementia. We found that individuals who
progressed from CIND accounted for 75% of the inci-
dent dementia cases. It is likely that for many of the
other 25% of incident dementia cases, we may have been
able to detect CIND prior to dementia with shorter
follow-up intervals. These findings highlight that a pe-
riod of mild impairment prior to dementia is likely de-
tectable in the majority of individuals. A point that is of-
ten overlooked is that many individuals remain mildly
impaired for years and may not progress to dementia.
Over 50% of individuals with CIND in the present
study did not progress to dementia during the time pe-
riod that they were followed. From this group, we may
be able to identify factors that delay progression to de-
mentia. It has been estimated that delaying the onset of
AD by 1 year in those at risk would result in about 1
million fewer cases by 2050,1 with the largest decrease in
the number of severe AD cases. So interventions, whether
behavioral or pharmaceutical, that can even modestly
delay progression from CIND to dementia may signifi-
cantly decrease the burden of dementia on patients, fami-
lies, and the health system.
One of the challenges of studying the outcomes of
mild impairment has been the variable rates of diagnostic
stability over time, regardless of the diagnostic nomencla-
ture used. In our sample, 12% of those with CIND
reverted to normal cognition at 1 of the follow-up assess-
ments. This rate of reversion to normal is virtually iden-
tical to that in another study32 that has used the same
assessment and diagnostic procedures used in ADAMS.








from CIND, OR (95%)
Baseline age 1.05 (1.00–1.12) 1.04 (0.99–1.11) 1.06 (1.00–1.14)a 1.01 (0.95–1.07)
Years of schooling 0.89 (0.82–0.96)a 0.89 (0.81–0.98)a 0.86 (0.77–0.97)a 0.99 (0.91–1.08)
Gender
Male 0.69 (0.39–1.21) 0.37 (0.15–0.94)a 1.64 (0.84–3.19) 0.59 (0.36–0.97)a
Female (ref ) 1.00 1.00 1.00 1.00
Race
Black 0.98 (0.50–1.95) 1.22 (0.58–2.57) 1.67 (0.78–3.57) 1.45 (0.59–3.56)
Nonblack (ref ) 1.00 1.00 1.00 1.00
Any APOE E4 alleles
Yes 2.20 (1.09–4.44)a 2.93 (1.68–5.13)c 2.65b (1.27–5.56) 2.76 (1.27–5.97)a




AD ¼ Alzheimer disease; CIND ¼ cognitive impairment, not dementia; OR ¼ odds ratio; CI ¼ confidence interval; ref ¼
reference.
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In a study31 that examined 2-year follow-up outcomes
using 16 different algorithm classifications for MCI in a
population-based sample, the rates of reversion to normal
varied from 18% to 45% across the range of diagnoses
indicating pathological decline; but in other studies using
algorithm diagnoses, the reversion rate was as high as
93%.33 These studies suggest that longitudinal outcomes
may differ based on the diagnostic criteria applied and
whether an algorithm versus a consensus conference
approach is used.9
Limitations of ADAMS include possible response
bias due to selective nonparticipation and attrition. This
is a potential risk for all longitudinal studies, especially
epidemiological studies of older individuals where comor-
bidities and mortality are common. To minimize
response bias, we used archived information from prior
interviews to develop response propensity models and
associated weighting adjustments. Due to the relatively
small sample size in some age groups, the estimates of
incidence lack some precision. Also, due to the relatively
small numbers in any given geographic region, we could
not assess regional differences in outcomes. The higher
rate of attrition for the Hispanic group may limit the
generalizability of the results for that ethnic group. Diag-
nostic errors may have occurred due to inaccuracies in
both the diagnostic criteria and in the assignment of the
diagnosis by the consensus panel. The diagnostic criteria
particularly for cognitive impairment without dementia
are in the developmental stages and require further vali-
dation.11,34 We attempted to minimize variability in the
assignment of the clinical diagnosis within this study by
using assessment teams based at a single site who used
methods established in previous epidemiological studies
and by using 1 common expert case review panel.
Our findings show that combined dementia and
CIND affect a very large segment of the elderly popula-
tion. Those with CIND are at particularly high risk of
progressing to dementia; however, at least within a 6-year
period, not all individuals with CIND progress to de-
mentia. Our estimates of national incidence rates for
CIND and dementia may serve as a benchmark against
which to measure the effectiveness of potential future de-
mentia prevention interventions.
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